EndoResFellow said:Worth answering the question that was asked rather than the one behind it.
Agreed, and one caution: a single measurement is not a measurement. Anything that moves day to day needs a trend before it means anything at all.
HealthEcon_DC said:NASH/MAFLD therapeutic landscape and liver and MASH: GLP-1 agonists are emerging as potential first-line NASH therapy.
This answered a question I did not know how to ask. Printing the relevant bit and taking it with me.
EndoResFellow said:Worth answering the question that was asked rather than the one behind it.
Filing a mild objection. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit. This treats a plausible mechanism as a demonstrated one. Plausible is where you start looking, not where you stop.
Janoshik Analytical — Independent Testing
Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.
Verify Your PeptidesGL Biochem (Shanghai) Ltd. — Direct Manufacturer
Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.
Browse GL BiochemOne concrete data point for the thread. Give anything pharmacological four weeks before you judge it, and give anything measured weekly a four-point rolling average before you call it a trend.
Moderator note: a post naming a supplier has been edited. Discuss suppliers in the review sections, not here. Tagging this one for the weekly digest.